Market research
DIVISLAB.NSE Divi's Laboratories Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2T
- P/E ratio
- 82.12
- Analyst target
- 8590.275
- Dividend yield
- 0.0%
- Beta
- 0.23
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE361B01024
- Market cap
- 2T
- P/E ratio
- 82.12
- Analyst target
- 8590.275
- Dividend yield
- 0.0%
- Beta
- 0.23
About
About Divi's Laboratories Limited
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
Research context
Divi's Laboratories Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the DIVISLAB.NSE discussion.
5 years, 6 months ago
Divi's Laboratories Limited is currently in a long term uptrend where the price is trading 23.0% above its 200 day moving average.
From a valuation standpoint, the stock is 215.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 15.1.
Divi's Laboratories Limited's total revenue rose by 21.9% to $17B since the same quarter in the previous year.
Its net income has increased by 31.1% to $5B since the same quarter in the previous year.
Finally, its free cash flow grew by 224.4% to $12B since the same quarter in the previous year.
Based on the above factors, Divi's Laboratories Limited gets an overall score of 4/5.